Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020

Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) has announced significant updates on their investigational gene therapy, VY-AADC, for advanced Parkinson's disease, with presentations at the International Parkinson and Movement Disorder Virtual Congress from September 12-16, 2020. Key findings include three-year safety and clinical outcomes from the PD-1101 trial and 24-month results from the PD-1102 trial. Moreover, Voyager will participate in upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 9, 2020. More details can be found on their website.

New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease

Voyager to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentations at the International Parkinson and Movement Disorder Virtual Congress 2020 taking place on September 12-16, 2020. The presentations include new two- and three-year data related to its VY-AADC gene therapy treatment for Parkinson’s disease being developed in collaboration with Neurocrine Biosciences:

• Three-Year Safety and Clinical Outcomes from the PD-1101 Trial of AADC Gene Therapy for Advanced Parkinson’s Disease
  Poster #879: Update on Genetics of Movement Disorders
  September 13, 2020, 10:30–12:30 p.m. ET (10-minute prerecorded presentation)
               
• AADC Gene Therapy Administered via a Posterior Approach: 24-month Results from the PD-1102 Trial in Advanced Parkinson’s Disease
  Poster #889: Poster Tour
  Launches on-demand on September 11, 2020, 8:00 a.m. ET (5-minute prerecorded presentation)

Additionally, the company plans to participate in the following virtual investor conferences in September:

• Wells Fargo 2020 Virtual Healthcare Conference
  Wednesday, September 9 at 1:20 p.m. ET
  
  
• Cantor Virtual Global Healthcare Conference
  Wednesday, September 16 at 2:40 p.m. ET
  
  
• Morgan Stanley 18th Annual Global Healthcare Conference
  Friday, September 18 at 10:15 a.m. ET

The webcast sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Investor Relations:   
Paul Cox
VP, Investor Relations
857-201-3463
pcox@vygr.com   

Media:
Sheryl Seapy
W2Opure
949-903-4750
sseapy@purecommunications.com

FAQ

What are the latest findings from Voyager Therapeutics regarding VY-AADC for Parkinson's disease?

Voyager Therapeutics has presented new data showing three-year safety and clinical outcomes from the PD-1101 trial and 24-month results from the PD-1102 trial for VY-AADC in advanced Parkinson's disease.

When is the International Parkinson and Movement Disorder Virtual Congress?

The Congress will take place from September 12-16, 2020, featuring presentations on VY-AADC.

What investor conferences will Voyager participate in September 2020?

Voyager will participate in the Wells Fargo Healthcare Conference on September 9, Cantor Virtual Global Healthcare Conference on September 16, and Morgan Stanley's Global Healthcare Conference on September 18.

How can I access the presentations by Voyager Therapeutics?

Presentations and webcasts can be accessed from the Investors & Media section of Voyager’s website, where replays will be archived for at least 30 days.

What is the significance of the PD-1101 and PD-1102 trials?

The PD-1101 trial provides important three-year safety data, while the PD-1102 trial presents two-year results, both of which are crucial for understanding the effectiveness of VY-AADC in treating advanced Parkinson's disease.